Kodak’s plate and inkjet sales dropped 7% in Q3 compared to a year earlier, but rapid growth in its advanced materials division meant that as a whole Kodak reported a 3% like for like increase in sales.
Revenues came in at $276 million compared to $269 million thanks to a 21% increase in revenue from its advanced materials and chemicals division. This produced all manner of films aided now by pharmaceuticals and printed batteries, both of which are in a start up phase.
However, print remains the dominant revenue generator bringing in revenues of $165 million in Q3 down from £177 million at this point in 2025. Operational Ebitda was $2 million higher at $31 million as a $7 million operational loss in print was countered by a $5 million contribution from advanced material and a $4 million contribution from the brand licensing operations.
CEO and executive chairman Jim Continenza explained that this had been a strong performance in the third quarter, saying: “We continue to execute our long term plan and are seeing a return on our ongoing investments. Our primary growth engine, AM&C, is now our fastest growing, most profitable unit. Our print business has performed well for the year to date despite challenging economic conditions. And, most importantly, we generated $27 million in cash for Q3, an important indicator of the operational strength of our business. Looking forward, we’re focused on continuing to invest in our core businesses and finishing the year with profitable growth.”
The pharmaceutical business operates a web store for pharmaceutical, life science and biotech customers to order conveniently, adding a saline solution to the range of reagents and other products from its FDA registered facility. It was a severe shortage of pharmaceutical saline following a hurricane in the US that prompted Kodak to become a manufacturer of the product.
While this is perhaps not a direction nor a product those in print or photography would expect from Kodak, the company has created a short film to explain how plates, film and pharmaceuticals are part of Kodak’s future direction.
